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Abstract
Simulating drug binding and unbinding is a challenge, as the rugged energy landscapes that
separate bound and unbound states require extensive sampling that consumes significant
computational resources. Here, we describe the use of interactive molecular dynamics in
virtual reality (iMD-VR) as an accurate low-cost strategy for flexible protein-ligand docking.
We outline an experimental protocol which enables expert iMD-VR users to guide ligands
into and out of the binding pockets of trypsin, neuraminidase, and HIV-1 protease, and rec-
reate their respective crystallographic protein-ligand binding poses within 5–10 minutes.
Following a brief training phase, our studies shown that iMD-VR novices were able to gener-
ate unbinding and rebinding pathways on similar timescales as iMD-VR experts, with the
majority able to recover binding poses within 2.15 Å RMSD of the crystallographic binding
pose. These results indicate that iMD-VR affords sufficient control for users to carry out the
detailed atomic manipulations required to dock flexible ligands into dynamic enzyme active
sites and recover crystallographic poses, offering an interesting new approach for simulating
drug docking and generating binding hypotheses.
1 Introduction
Computational researchers across a wide range of fields are becoming increasingly aware of
their responsibility to explore low-cost simulation methodologies whose energy and hardware
demands are environmentally sustainable. [1] Whilst the molecular dynamics (MD) approach
to biomolecular simulation [2–5] and protein ligand-binding [6–12] has exploded in recent
years, [13] the computational cost of MD-based approaches remains significant–a result of the
fact that proteins are high-dimensional systems characterized by many local energy minima
separated by a rugged landscape.
Building on previous work constructing interactive simulation frameworks (e.g., led by
Brooks [14–16], Wilson [17], Schulten [18, 19], and others [20–22]), we have been exploring
interactive molecular dynamics in virtual reality (iMD-VR) as a low-cost strategy for
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narupaxr. The videos referred to within the text are
investigating biomolecular problems like protein-ligand binding. Part of the attraction of
an MD-based approach is the fact that it can capture movement and flexibility of both the
protein and the ligand. Our open-source iMD-VR framework Narupa [23] allows users to
interactively visualise and manipulate the molecular dynamics of real-time simulations
within a virtual environment with atomic-level precision. The iMD-VR approach recog-
nizes that the neural nets of the human brain, trained over several aeons, offer extremely
sophisticated machinery for efficiently undertaking tasks linked to 3D insight, spatial navi-
gation, and manipulation, with energy demands that are a fraction of those required by
sophisticated hardware-accelerated machine-learning frameworks. Narupa enables humans
to utilize their 3D spatial awareness skills, and their ability to undertake ‘on-the-fly’ reason-
ing, to perform sophisticated operations on complex three-dimensional molecular struc-
tures, giving them the ability to move molecular systems between different regions of
configuration space. In previous work, we have demonstrated that iMD-VR has acceleration
benefits for various 3D molecular tasks compared to two-dimensional interfaces. [23, 24]
The ability to physically reach out and manipulate simulated systems as if they were tangible
objects gives users the opportunity to explore molecular transformations, mechanisms, and
rare events that may otherwise be inaccessible using conventional high-performance com-
puting (HPC) MD simulations. While we have previously demonstrated the potential of
iMD-VR to generate dynamical pathways in small systems, it remains to be seen whether
iMD-VR is sufficiently intuitive and enables enough control for researchers to undertake
more complex tasks.
In this article, we focus on applying Narupa to unbinding and rebinding small molecules
to proteins, as illustrated in Fig 1. Applying iMD-VR to protein-ligand systems requires
moving a simulation between thermodynamically and kinetically distinct states (i.e.,
bound and unbound). This requires sophisticated three-dimensional spatial reasoning: the
protein binding pocket needs to be located, and the ligand orientated such that key contacts
to specific residues are properly recreated. We evaluate the utility of iMD-VR to facilitate
such manipulations through applications to three protein-ligand systems of increasing
complexity, and investigate the extent to which iMD-VR ‘experts’ and ‘novices’ were able
to reversibly generate protein unbinding and rebinding pathways and recover crystallo-
graphic ligand poses for the systems shown in Fig 1. The results of the experimental proto-
col outlined herein show that iMD-VR users can quickly unbind and rebind ligands to
proteins and recover experimental protein-ligand structures. For example, we show that an
hour-long training session with an expert user enables novice iMD-VR users to recover
the original binding poses for several different protein-ligand systems. We have established
that the pathways generated by iMD-VR users are reproducible, and that the binding poses
they recover are stable when used to initiate MD simulations over longer simulation
timescales.
iMD-VR represents a relatively new approach to simulating drug binding, since it involves
a fully (or predominantly) flexible dynamic system and also does not require predefining a CV
along which to carry out biased molecular dynamics simulations. [25] Instead, the researcher
simply ‘draws’ the desired pathway by manipulating a complex system between different states.
This approach has the potential to accelerate the exploration of pathways through high-dimen-
sional configuration space. Overall, our tests show that a well-designed iMD-VR setup enables
expert and novice users alike to accelerate complex 3D state changes of biomolecular systems.
Our results suggest that iMD-VR tools are sufficiently intuitive and provide adequate control
to enable users to recover experimentally derived bound complexes. Moreover, the fact that
the sampled pathways are reproducible suggests that they are not too far from the equilibrium
ensemble.
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2 Methods
2.1 System selection
The systems selected for the studies outlined herein include, at one extreme, those that have
well-characterized binding modes, where a user with prior knowledge of the system can use
iMD-VR to sample binding and unbinding pathways. At the other extreme, we sought to push
the limits of the iMD-VR tools and examine more complex protein-ligand systems. The three
systems we chose are shown in Figs 1 and 2 and are described below in order of increasing
complexity.
2.1.1 Trypsin. The first protein-ligand system is the enzyme trypsin with a benzamidine
ligand. Trypsin is a well-studied serine protease hallmarked by a catalytic triad consisting of
Fig 1. Interactive protein-ligand rebinding using iMD-VR. The top panel shows a schematic of Narupa, the open-source
multiperson iMD-VR framework used to carry out the studies described herein, showing two participants using handheld wireless
controllers to manipulate a real-time MD simulation of neuraminidase and oseltamivir. More information on the Narupa setup is
available in ref 15. The bottom panel shows a three-dimensional representation of the binding pockets of each of the three protein
systems interactively undocked and redocked, each bound to a ligand. The trypsin graphic (A) highlights the network of hydrogen
bond interactions from Asp189, Ser190, and Gly219 to benzamidine (based off PDB code 1S0R). The neuraminidase graphic (B)
highlights the hydrogen bonds between oseltamivir and both the 150-loop and a positively-charged trio of arginine residues of
neuraminidase (based off a mutated neuraminidase structure derived from PDB code 2QWK). The HIV-1 protease graphic (C)
highlights the hydrogen bonds between the hydroxyl group of amprenavir with both Asp25A and the protonated form of Asp25B
(based off PDB code 1HPV). For HIV-1 protease, the protein ‘flaps’ have been highlighted in purple.
https://doi.org/10.1371/journal.pone.0228461.g001
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histidine, serine and aspartic acid. As shown in Fig 1A, a secondary motif of the trypsin bind-
ing pocket is an additional aspartic acid residue (at position 189) that stabilises the positively
charged amino acids, binding a peptide chain in a pose that allows for specific cleavage of the
carboxyl-side chain in which these amino acids are present.[26] Asp189 is charged, partially-
buried, and is surrounded by a water network that favours desolvation.[27–29] Trypsin inhibi-
tors can exploit this by mimicking positively-charged residues and forming an electrostatic
contact with Asp189, an interaction further stabilized by a network of hydrogen bonds to
Ser190 and Gly216 (Fig 1A).[30] The binding mode between trypsin and one of its inhibitors,
benzamidine, has relatively fast kinetics and is therefore often applied as an initial use case for
theoretical methods.[31–34] From an iMD-VR perspective, the trypsin-benzamidine system
represents a binding mode where users do not need to induce significant conformational
changes in the protein, and the ligand has only one rotatable bond. In effect, a user need only
move the benzamidine out of the binding pocket before placing it back, making trypsin a rela-
tively simple test case for iMD-VR.
Fig 1A shows a three-dimensional binding mode of benzamidine in the secondary binding
pocket of trypsin, illustrating how residues Asp189, Ser190, and Gly216 bind to ligands (based
off PDB code 1S0R). Fig 2A shows the two-dimensional binding mode of two ligands, benza-
midine and indole-amidine, into trypsin. Supplementary video A.1 in S1 File (https://vimeo.
com/354833443) shows an example of an expert iMD-VR user unbinding and rebinding ben-
zamidine from trypsin in iMD-VR.
Fig 2. Summary of iMD-VR docking tasks. The ligands that were interactively unbound and rebound in a series of user tests, two for each of the three
systems: Trypsin (A), Neuraminidase (B), and HIV-1 Protease (C). For each protein system, we devised two docking tasks, a training phase (where a
trace representation of the ligand in the bound pose was present to guide users as shown in supplementary videos A–C in S1 File), and a testing phase,
where no trace atoms were shown. For the testing tasks, parts of the ligand which interact with key residues have been highlighted in lilac. For proteins
A and B, where the testing task ligand differs from training, the shared scaffold between the two ligands is highlighted in green.
https://doi.org/10.1371/journal.pone.0228461.g002
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2.1.2 Neuraminidase. H7N9 neuraminidase is a glycoside enzyme found on the surface
of influenza virions that catalyzes the hydrolysis of sialic acid residues, a process integral to
influenza virus mutation.[35, 36] This strain was found in the influenza virus responsible for
the 2013 bird flu pandemic.[37] The process of influenza virus replication begins with the
virus attaching itself to the cell via the binding of hemagglutinin (a viral cell surface protein) to
sialic acid, found on the end of glycoproteins attached to the cell membrane. Once anchored,
the virus can enter the cell and hijack its machinery in order to replicate itself. After new
viruses have been manufactured, neuraminidase proteins cleave sialic acid groups from cellu-
lar glycoproteins, breaking the anchor between the virus and the host cell, freeing the new
viruses to infect other cells. In recent years, there has been extensive research on the discovery
of inhibitors that mimic sialic acid, thereby preventing the cleavage of sialic acid residues by
neuraminidase and obstructing the release of new viruses. [38, 39] Oseltamivir (Tamiflu) is a
transition state analogue of sialic acid and licensed therapy for influenza that binds to a triad
of arginine residues in the neuraminidase active site (Arg118, Arg292, and Arg371) via its car-
boxylate group. [40] In addition to this, a crucial loop opening and closing mechanism, known
as the 150-loop motion, is involved in the unbinding and rebinding of oseltamivir (Fig 1B).
[41, 42] From an iMD-VR perspective, the binding of oseltamivir to neuraminidase represents
a more complex task than the trypsin-benzamidine system for two reasons: (1) Given that
150-loop movement is imperative to binding, this backbone motion needs to be carried out by
the iMD-VR user; (2) With eight rotatable bonds, oseltamivir has considerably more confor-
mational flexibility than benzamidine, making it more of a challenge to re-establish the correct
bound configuration.
Fig 1B shows a three-dimensional binding mode of oseltamivir in the active site of neur-
aminidase, illustrating how the 150-loop and arginine trio binds to ligands (based off a
mutated neuraminidase structure derived from PDB code 2QWK; details for how this was
done can be found in ref [37]). Fig 2B shows the two-dimensional binding mode of two
ligands, oseltamivir and zanamivir, into neuraminidase. Supplementary video B in S1 File
shows an example of an expert iMD-VR user unbinding and rebinding oseltamivir from
neuraminidase in Narupa.
2.1.3 HIV-1 protease. HIV-1 protease is a viral aspartyl protease essential to the life cycle
of HIV, responsible for cleaving precursor polypeptides into functional proteins, making it an
attractive drug target for preventing HIV maturation. Structurally, HIV-1 protease is a homo-
dimer that shares a single active site between two protein subunits, each of which contributes
a catalytic aspartic acid. Mechanisms for HIV-1 protease cleavage of precursor proteins have
been proposed [43]; however, it is broadly understood that the two aspartic acid residues each
act as an acid or base respectively, activating a water molecule that then goes on to break pep-
tide carbonyl bonds via nucleophilic attack. Sulfonamides are a class of drug licensed for the
treatment of HIV that hydrogen bond to the catalytic aspartic residues and thus block protease
activity [44], an example of which is amprenavir. Functionally, the two aspartic acids are
thought to primarily exist in a monoprotonated state, especially when in the presence of an
inhibitor [45], although it has been debated which tautomer favours amprenavir binding. [46–
50] The HIV-1 protease active site is gated by two beta-hairpin flaps that shift through a series
of different conformational states before ligand binding. [51] Therefore, this task requires
iMD-VR users to move these flaps into an open position to guide amprenavir out, and then
carefully place the loops back without disrupting their secondary structure. From an iMD-VR
perspective, the motion of these flaps, combined with the higher rotational flexibility of ampre-
navir, makes this a particularly challenging binding task. Fig 1C shows a three-dimensional
binding mode of amprenavir in the active site of HIV-1 protease, illustrating how Asp25A and
Asp25B bind amprenavir (based off PDB code 1HPV). The active site flaps are coloured in
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purple. Fig 2C shows the two-dimensional binding mode of amprenavir into HIV-1 protease.
Supplementary video C in S1 File (https://vimeo.com/354834013) shows an example of an
expert iMD-VR user unbinding and rebinding amprenavir from HIV-1 protease in Narupa.
2.2 Overview of binding and rebinding tasks
Using these candidate protein-ligand systems, we carried out iMD-VR tests. Users were split
into expert and novice cohorts. Expert users had extensive experience using iMD-VR to
interact with molecules and had some degree of familiarity with the protein-ligand systems
described in this paper. The experts first tested the viability of using iMD-VR to generate
ligand unbinding and rebinding pathways. Expert iMD-VR studies were carried out to estab-
lish whether the original crystallographic structure could be re-established for each task. Then,
a cohort of novice users were asked to carry out a series of unbinding and rebinding tasks, in
order to control for the experts’ familiarity with iMD-VR tools and the selected systems. This
novice users had little experience using iMD-VR but did have a scientific background in bio-
molecular simulations.
2.2.1 Expert user tests. Expert iMD-VR users were tasked with unbinding and rebinding
three ligands from the binding pockets of three proteins: trypsin, neuraminidase, and HIV-1
protease, detailed in Section 2.1. Fig 1 shows a three-dimensional representation of each of
the three experimentally derived poses that expert users were asked to recreate. In these tasks,
experts were initially given a faint trace of the ligand atoms in the correct pose, providing a
visual indication of where the ligand sits in the crystallographic binding pose. Experts could
freely switch between interacting with either a single atom at a time or a group of atoms
together (e.g., moving one atom of the ligand or the center of mass of the entire ligand at
once). Experts could also add or remove positional restraints to atoms, such as when manipu-
lating the active site flaps during the HIV-1 protease task. Supplementary videos A-C in S1 File
show experts unbinding and rebinding small molecules from trypsin, neuraminidase and
HIV-1 protease, and also show the guide trace for the position of the ligand atoms. [23]
2.2.2 Novice user tests. Once the iMD-VR unbinding and rebinding pathways in Narupa
had been established by the expert users, novice users were recruited to complete unbinding
and rebinding tasks with each of the three protein systems. Novice users interacted with each
system until they felt they had correctly established a binding pose, spending approximately
five minutes on each task. The protein-ligand systems were given in order of increasingly com-
plexity. Fig 2 gives a summary of tasks novice participants were asked to complete. We
recruited a total of ten novice participants in two cohorts of five (‘cohort one’ and ‘cohort
two’). Cohort one completed tasks described in 2.3.1–2.3.4. Cohort two completed tasks
described in 2.3.1–2.3.4 and 2.3.6. More detailed demographic and task information can be
found in the S1 File.
To ensure there was a comparable level of proficiency with the Narupa iMD-VR interface
prior to attempting protein-ligand binding, novice participants were first placed in a simula-
tion of C60 molecules and given an opportunity to familiarize themselves with the controls and
the interaction, as was done in previous studies. [24] Additionally, before interacting with each
of the three protein systems described in Section 2.1, we took advantage of the multiplayer fea-
ture of Narupa: novice users were placed in the same iMD-VR simulation as the expert user
(as shown in the Fig 1 schematic), where they could see a fully three-dimensional representa-
tion of the bound poses shown in Fig 1. To ensure the novices had a comparable level of
knowledge of each system, while co-habiting the simulation space, the iMD-VR expert gave a
brief background on the system and highlighted the interactions shown in Fig 1.
PLOS ONE Protein-ligand binding in virtual reality
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Once the system had been introduced, participants were asked to complete a ‘training’
ligand unbinding-rebinding task. During the training phase, novices had a trace of the ligand
atoms in the bound pose to help guide them. Next, participants were given a ‘testing’ ligand
unbinding and rebinding task. A summary of the training and testing tasks for each of the
three protein systems is shown in Fig 2. In these experiments, no trace atoms of the ligand
were present, meaning that participants had to rely more on their chemical insight to find the
correct binding pose. To control for learning effects during the testing phase of trypsin and
neuraminidase binding, novices were asked to bind different ligands from those used during
training. The alternative ligands were chosen on the basis of key interactions remaining
between the ligand and protein in the training portion of the study (highlighted in lilac in Fig
2A and 2B) and sharing structural similarities (highlighted in green in Fig 2A and 2B). Due to
a lack of availability of an appropriate alternative ligand to amprenavir, and because of the
heightened complexity of the task owing to the number of rotatable bonds amprenavir con-
tains, amprenavir was used for both the training and testing phases of the HIV-1 protease sys-
tem. Novice users also had a more limited user interface, where they only had the option of
interacting with a single atom at a time and could not apply or remove positional restraints.
2.3 iMD-VR simulation set up
The Narupa selection utility, shown in supplementary videos A–C in S1 File, allows users to
select and apply visualization and interaction settings to a subset of atoms in a system. For all
systems, the following selections were created: (a) protein backbone atoms, (b) key active site
residues, (c) ligand atoms. Each system had some specific features, detailed below. Further
simulation-specific details can be found in the S1 File.
2.3.1 Trypsin and benzamidine (expert task and novice training task). This task (Fig
2A, ‘Training’) was completed by both experts and novices. Given the relatively simple binding
mode between benzamidine and trypsin, where the protein does not need to be manipulated
by the user, the entire protein backbone was held in place with a positional restraint (details
can be found in the S1 File). To enable the user to visually identify the location of the active
site in the protein, residues Asp189 and Ser190 were fully rendered and the backbone oxygen
of Gly219 was shown, similar to the representation shown in Fig 1A. Additionally, supplemen-
tary video A.1 in S1 File shows the rendering scheme used for trypsin and benzamidine. For
the remaining residues, only the protein backbone was rendered. A trace of benzamidine in
the crystallographic pose was used as a visual indication of where the ligand binds, encourag-
ing the user to re-establish the original bound pose as closely as possible.
2.3.2 Trypsin and indole-amidine (novice testing task). Following the training phase,
novices were asked to bind indole-amidine into trypsin (Fig 2A ‘Testing’). Indole-amidine was
selected as an alternate ligand for novices to bind as it contains the benzamidine moiety and
adopts the same binding mode to Asp189, Ser190 and Gly219. However, unlike benzamidine,
indole-amidine has a non-symmetrical extended scaffold that needs to be correctly orientated.
This testing task used the same protein restraints and rendering scheme as the training task
with trypsin and benzamidine (Section 2.3.1). However, no trace atoms were shown.
2.3.3 Neuraminidase and oseltamivir (expert task and novice training task). This task
was completed by both experts and novices. Binding oseltamivir requires a small amount of
manipulation of the protein, as the positions of the 150-loop residues over the ligand need to
be carefully maintained. However, as no significant shift in the tertiary structure of neuramini-
dase is required, all backbone atoms were held with a positional restraint (details can be found
in the S1 File). To aid in ensuring the 150-loop was correctly placed, two strategies were
adopted. First, residues Asp151 and Arg152 of the 150-loop were fully rendered so the user
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could see their position. Second, a trace representation of the position of the 150-loop residues
in the closed position was rendered so the user could see where they should be placed. Addi-
tionally, to show if a hydrogen bond between the carboxylic acid of oseltamivir and the argi-
nine trio of the neuraminidase binding pocket had been established, Arg118, Arg292, and
Arg371 were also fully rendered. For the remaining residues, only the backbone atoms were
shown. A trace of the oseltamivir atoms in the correct position was used as a visual indication
of where the ligand binds, ensuring that the original binding pose could be closely replicated.
Supplementary video B in S1 File shows the rendering scheme used in Narupa for neuramini-
dase and oseltamivir.
2.3.4 Neuraminidase and zanamivir (novice testing task). Following the training phase,
novice users were asked to bind zanamivir to neuraminidase. Zanamavir was selected as the
second binding task as it is a chemical analogue to oseltamivir, sharing the same ring scaffold,
carboxylic acid group, and hydrogen-bonding contacts to the 150-loop. However, zanamivir
does exhibit some structural differences from oseltamivir; therefore, this task requires the user
to recognize the similarity in binding modes between the two drugs. As discussed below, we
used this particular task to examine the results obtained if we removed backbone restraints
entirely. The same protein rendering scheme as neuraminidase and oseltamivir was used (Sec-
tion 2.3.3), however, no trace atoms were present.
2.3.5 HIV-1 protease and amprenavir (expert task). Binding small molecules to HIV-1
protease requires a significant shift in the backbone atom positions, altering the structure from
closed to open. During the simulation, the user could toggle a positional restraint force on the
active site flaps, allowing them to be held in place once an open or closed conformation had
been established. An additional strategy to aid in the opening and closing of HIV-1 protease
was to render trace atoms of the protein backbone in the position of the active site flaps in
both the closed position and the open position, giving the expert user a visual indication of the
range of motion the loop has between the two states, as well as allowing the user to closely re-
establish the original closed conformation once amprenavir had been redocked; details on
how this was done can be found in the S1 File. Aside from the active site beta-hairpin flaps,
which were manipulated by the expert user during the simulation, the protein backbone atoms
were held by backbone restraints. Details on the positional restraints can be found in the S1
File. Key contact residues Asp25A and Asp25B were fully rendered; the remaining amino acids
only had their backbone atoms shown. A trace atom representation of amprenavir was used as
a visual indication of where the ligand binds, ensuring the original bound conformation could
be re-established.
2.3.6 HIV-1 protease and amprenavir (novice testing and training tasks; cohort two
only). Novice users from cohort two, totalling five participants, were asked to unbind and
rebind amprenavir twice, once with the aid of trace atoms and once without. All other back-
bone atoms in the protein were positionally restrained. To streamline the task, novices were
not required to open and close the HIV-1 protease flaps prior to and after binding amprenavir,
instead starting from an HIV-1 protease conformation that had been pre-opened by an expert
using iMD-VR and held with a positional restraint. Details of this can be found in the S1 File.
Both the testing and training binding tasks used the same rendering scheme as the expert user
tests (Section 2.3.5)–the only difference between the two tasks was the presence of trace atoms.
2.3.7 Backbone restraints. During iMD-VR, users can apply force to any atom in the sys-
tem–including those integral to the protein tertiary or quaternary structure. In order to ensure
that the protein tertiary structure required for binding was not distorted, a positional restraint
was applied to the backbone atoms in the proteins. To evaluate the impact of these restraints,
we removed the backbone restraints for cohort two during the neuraminidase and zanamivir
testing phase. A comparison of task completion between cohort one and cohort two for
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undocking and redocking zanamivir from neuraminidase can be found in S3 Fig in S1 File.
These results, discussed in further detail in the S1 File, show that careful iMD-VR users (expert
and novice alike) were able to carry out binding and unbinding tasks without positional
restraints. For analysis of iMD-VR trajectories, we observed that PCA carried out on iMD-VR
trajectories which utilized positional restraints produced better results for the binding/unbind-
ing pathways of interest, owing to diminished noise from the backbone fluctuations.
2.4 Analysis of iMD-VR results
For both the expert and novice interactive unbinding and rebinding tasks, trajectories of the
protein-ligand system were recorded, taking a snapshot of the system every 0.25 ps. iMD-VR
trajectories were analysed using an RMSD calculation protocol (described in the S1 File). The
RMSD was used to: (1) analyse the expert trajectories to see how the system is changed from a
bound to unbound and back to bound state; (2) analyse novice trajectories to identify how
close a user got to recreating the starting pose; and (3) analyse whether the recovered binding
poses were stable. Specifically, we selected an iMD-VR frame with an RMSD close to the start-
ing coordinates and used it to initialize a longer timescale (200 nanoseconds) MD trajectory.
Further details can be found in the S1 File.
To qualitatively assess the reproducibility of the binding pathways users explored using
iMD-VR, we utilized a Principal Component Analysis (PCA) tool called PathReducer, [52]
which takes as input an xyz file containing a series of molecular structures (in this case, an
iMD-VR-generated trajectory) and outputs the set of principal coordinates which captures
the most structural variance in the fewest coordinates. In effect, PathReducer collapses a 3N-
dimensional (where N = number of atoms) trajectory into a visualisable path which spans two
or three dimensions. Further details of this can be found in the S1 File.
3. Results and discussion
3.1 Expert unbinding and rebinding tasks
3.1.1 Trypsin. Fig 3A shows the RMSD of the expert user-generated trajectory of benza-
midine unbinding and rebinding to trypsin, alongside the top two and top three PCs along the
trajectory path. The RMSD plot of benzamidine shows that the original binding pose was
recovered by the expert user, as the RMSD between the ligand at the end of the trajectory and
the beginning is very low. The PCA results for this system showed that the direction of PC1
(the PC that captures the most structural variance along the trajectory) corresponds predomi-
nantly to motion of the ligand away from the protein. The value of PC1 at the end of the trajec-
tory is very similar to that at the beginning, which is more evidence that this user was able to
replicate the original bound pose of the drug. PC2 and PC3 correspond to fluctuations of the
backbone and side chains not in the active site of the protein, hence the trajectory not return-
ing precisely to its initial value of these PCs. Supplementary animation A in S1 File (https://
vimeo.com/354828618) shows the trajectory generated by an expert user (31 picoseconds of
simulation in total). Fig 4A shows the RMSD of an expert-generated rebound trypsin-benza-
midine complex over 200 nanoseconds of production MD, after solvation, minimization and
equilibration as described in the S1 File, establishing that the iMD-VR produces stable poses
for this system.
Expert study subjects were able to unbind benzamidine in under 5 picoseconds and obtain
the rebound pose within another 5 picoseconds (Fig 3A). Using our computing architecture,
as described in the S1 File, we were able to achieve MD simulation rates of 4.45 picoseconds
per minute of real time, meaning that benzamidine could be unbound and rebound on the
scale of minutes. As such, this demonstrates the efficiency with simulations can be interactively
PLOS ONE Protein-ligand binding in virtual reality
PLOS ONE | https://doi.org/10.1371/journal.pone.0228461 March 11, 2020 9 / 21
pushed between two distinct states. Trypsin-benzamidine binding events have previously been
observed to take nanoseconds of simulation time [32], and theoretical calculations of trypsin-
benzamidine unbinding rate constants, koff, predict millisecond dissociation times [31, 33]. To
unbind or rebind benzamidine, the user does not need to make any major conformational
changes to the binding site of trypsin, so completing this task was a matter of applying suffi-
cient force to break the relatively weak electrostatic contacts between benzamidine and
Asp189 and continuing to apply this force until the ligand had fully dissociated from the pro-
tein (supplementary video A.1 in S1 File). On rebinding, the user had to take care to keep the
orientation of benzamidine such that the charged amidine group is pointing towards the bot-
tom of the pocket. If the user attempted to bind benzamidine with the benzyl group directed
towards the positively-charged Asp189 residue the ligand would be repelled out of the binding
pocket, demonstrating the real-time responsiveness of iMD-VR to energetically unfavourable
input, as shown in Supplementary video A.2 in S1 File. The video shows how, after being
guided out of the binding pocket and replaced in an incorrect orientation, the N1 and N2 of
benzamidine fail to form electrostatic contacts to Asp189, and is subsequently repelled out of
Fig 3. Recovering binding poses of three protein-ligand systems using iMD-VR. Left: Ligand RMSD of iMD-VR generated
trajectories by experts (compared to starting coordinates): (A) trypsin and benzamidine, (B) neuraminidase and oseltamivir, and (C)
HIV-1 protease and amprenavir. For neuraminidase, the RMSD of the 150-loop residues is shown in blue. For HIV-1 protease, the
RMSD of the active site flaps backbone atoms is shown in blue. Right: The top two (left plots) and top three (right plots) principal
components (PC1-3) for representative trajectories of the three protein-ligand systems. Time is represented for each trajectory by the
colour of the plot, starting at purple for the beginning of the trajectory and yellow for the end, passing through blue and green in
between.
https://doi.org/10.1371/journal.pone.0228461.g003
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Fig 4. Ligand RMSD over 200 nanoseconds of molecular dynamics. Showing the RMSD of each of the three ligands
(compared to the initial solvated, minimized and equilibrated bound coordinates) during 200 nanoseconds of
molecular dynamics simulation. From top to bottom: (A) benzamidine (in trypsin), (B) oseltamivir (in
neuraminidase), and (C) amprenavir in HIV-1 protease.
https://doi.org/10.1371/journal.pone.0228461.g004
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the binding pocket, moving towards the HE1 of His57 in Trypsin, where it remains in a tran-
siently stable pose over at least 200 ps, as shown in S2-A1 Fig in S1 File. Supplementary video
A.2 in S1 File shows the expert utilizing the 3D interface of Narupa to identify those amino
acids with which the amidine group interacts with. This alternate binding mode, in which ben-
zamidine favours the catalytic triad and polar residues surrounding the binding pocket is simi-
lar to previous observations by Buch et al. [32]. S2-A2 Fig in S1 File shows how it was possible
for the expert user to apply continuous force to the benzamidine when rebinding, guiding it
past the cluster of hydrophilic groups and into the protein core and moving it out of the pro-
tein via an alternate opening. Whilst the kinetic barriers for these pathways are likely to be
very large; they nevertheless show the ability of iMD-VR to quickly enable exploration of new
dynamical pathways.
3.1.2 Neuraminidase. Fig 3B shows the RMSD of the expert-generated trajectory, along-
side PathReducer-generated principal component plots, establishing that the original binding
pose was recovered by the expert user. Similar to the trypsin system, PC1 is dominated by dis-
tances between atoms in the ligand and atoms in the protein, and so the variation along PC1
that can be seen along the trajectory path can be directly attributed to the removal of oseltami-
vir from the active site. PC2 and PC3 are again predominantly defined by distances between
atoms in residues of the protein far from the active site, and thus fluctuations of the associated
side chains lead to an offset in the pathway’s start and endpoints. Supplementary animation B
in S1 File (https://vimeo.com/354829098) shows the trajectory generated by an expert user (58
picoseconds of simulation time in total). Fig 4B shows the RMSD of an expert-generated
rebound oseltamivir-neuraminidase complex over 200 nanoseconds of production MD, after
solvation, minimization and equilibration as described in the S1 File, establishing that the
iMD-VR can produce stable poses for this system.
Using our computing architecture, as described in the S1 File, we were able to achieve MD
simulation rates of 4.51 picoseconds per minute of simulation time, meaning that oseltamivir
could be unbound and rebound on the scale of minutes of real time. Unbinding oseltamivir
requires applying enough force to break any charged contacts or hydrogen bonds formed
between the triad of positively charged arginine residues in the active site and the negatively
charged carboxylate group of oseltamivir. Upon unbinding, the interactions from the amine
group and carbonyl group of the drug and the two residues which comprise the 150-loop
(Asp151 and Arg152 –see Fig 1B) were also broken, causing the loop residues to dynamically
open as the drug leaves the active site as shown in supplementary video B in S1 File (https://
vimeo.com/354833800). The backbone of the 150-loop did not dynamically open when the
drug exited the active site as the backbone was held in place with restraints. When removing
oseltamivir from the binding site, the molecule would occasionally flip itself over, losing the
bound orientation. As such, when attempting to re-establish the correct binding pose, the user
needed to be extremely careful to ensure that binding interactions between the drug and the
150-loop residues were successfully recreated, allowing the drug to flip itself back into the cor-
rect pose; if the user was too forceful, the drug would enter the active site in the incorrect ori-
entation. A representation of oseltamivir ‘flipping’ as it is being removed from the
neuraminidase binding pocket can be found in S2-B1 Fig in S1 File. We observed that when
oseltamivir is back into the correct bound conformation, the two 150-loop residues will also
move back into the original configuration without any input from the user, demonstrating
how iMD-VR can dynamically reform energetically-favourable contacts.
3.1.3 HIV-1 protease. Fig 3C shows the RMSD of the expert-generated trajectory, along-
side generated principal component plots, establishing that the original binding pose was
recovered by the expert-user. The PCA results in this case are unique, as the user had to move
two flaps capping the active site prior to removal of the bound amprenavir (discussed in more
PLOS ONE Protein-ligand binding in virtual reality
PLOS ONE | https://doi.org/10.1371/journal.pone.0228461 March 11, 2020 12 / 21
detail below, see Fig 5). Each approximately linear segment of the PC plots corresponds to a
conformational change event: First, one flap is moved away from the active site. Then the sec-
ond flap is moved away from the active site. Finally, the ligand is removed from the active site.
This process is then reversed to rebind the ligand. The plots show strikingly similar pathways
for unbinding and rebinding, likely as the principal coordinates are each capturing a signifi-
cant movement of the protein backbone and thus ignoring smaller residue fluctuations; com-
paratively, PC2 and PC3 in the trypsin and neuraminidase systems do not have the same
starting and end points as they are ‘picking up’ protein fluctuations along the trajectory. Intui-
tively, PC1 is dominated by changes in distances corresponding to movement of the ligand out
of the protein, PC2 corresponds predominantly to distances between the first ‘flap’ and other
parts of the protein, and PC3 corresponds predominantly to distances between the second
‘flap’ and other parts of the protein. Supplementary animation C in S1 File (https://vimeo.
com/354829412) shows the trajectory generated by an expert user (61 picoseconds simulation
time in total). Fig 4A shows the RMSD of an expert-generated rebound HIV-1 protease-
amprenavir complex over 200 nanoseconds of production MD, after solvation, minimization
Fig 5. Snapshots along the interactive unbinding and rebinding of amprenavir into HIV-1 protease. The image in
the upper left shows the bound “start” pose. (a)–(c) shown snapshots as the user unbinds amprenavir; (d) shows the
unbound pose; and (e)–(g) shows snapshots as the user rebinds amprenavir. The corresponding RMSD time traces are
shown in the middle plot, identical to that shown in Fig 3c.
https://doi.org/10.1371/journal.pone.0228461.g005
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and equilibration as described in the S1 File. Some fluctuations to the RMSD value are observ-
able. Inspection of the 200 nanosecond trajectory shows that the hydroxyl group ‘flips’ its ori-
entation relative to the two catalytic aspartic acid residues, resulting in amprenavir adopting a
slightly different binding pose throughout the simulation, albeit still remaining in the binding
pocket of HIV-1 protease. Fig 5 shows a step-by-step breakdown of the process of unbinding
and rebinding amprenavir from HIV-1 protease, establishing that the iMD-VR can produce
stable poses for this system. In the apo form, the active site flaps of HIV-1 protease are thought
to dynamically switch between various open and closed conformations [51]. Upon binding,
the once-open flaps have a stabilizing effect by closing over the ligand. [53, 54] Experimental
estimates of koff for amprenavir binding to WT HIV-1 protease correspond to an average bind-
ing residence time on the scale of seconds [55, 56], making it a difficult transition to simulate
without some form of biasing. Using our computing architecture, as described in the S1 File,
we were able to achieve MD simulation rates of 4.45 picoseconds per minute of simulation
time, meaning that amprenavir could be unbound and rebound–including opening and clos-
ing the active site flaps—on the scale of minutes of real time.
Additionally, the Narupa selection language enabled the expert user to remove positional
backbone restraints and move the flaps into an open position, before replacing the restraints
and extracting amprenavir away from the binding pocket. To rebind amprenavir, the hydro-
gen bonding to Asp25A and Asp25B was reformed and, once the stable binding configuration
had been found, the user moved the beta-hairpin flaps back into the closed conformation,
again replacing the restraints. We note that we initially performed this task with a tautomer
of HIV-1 protease where neither Asp25 residues were protonated; in this state, amprenavir
seemed to favour a slightly different binding pose as its hydroxyl group no longer acts as a
hydrogen bond acceptor. To further investigate the difference in binding mode between the
two tautomers of HIV-1 protease, both were placed in Narupa with all positional backbone
restraints removed. The expert user observed both binding poses without interacting with the
system over 125 picoseconds of simulation time. In the monoprotonated HIV-1 protease sys-
tem, the hydroxyl group of amprenavir rigidly points towards the deprotonated aspartic acid
residue. Conversely, when both catalytic residues are deprotonated, the hydroxyl group fre-
quently flips between pointing at either aspartic acid, causing amprenavir to ‘sag’ in the active
site (see S2-C1 Fig in S1 File). The positively charged hydrogen on the protonated aspartic acid
appears to have a stabilising effect on the orientation of the hydroxyl group, whereas removing
the hydrogen causes the hydroxyl group to more easily flip as one orientation is no longer elec-
trostatically ‘penalized’ by the protonated residue. Nonetheless, it is worth highlighting that
Narupa enables qualitative observation of such binding dynamics in real time, demonstrating
that iMD-VR enables both manipulation of molecular dynamics and easy comprehension of
distinct dynamical behaviour in systems that have only small structural differences.
3.2 Novice unbinding and rebinding tasks
Fig 6 shows the minimum achieved RMSD of each small ligand novices tried to dock in both
‘training’ and ‘testing’ phases. For fully flexible simulations like these, which explore a range
of conformational space as a result of thermal fluctuations, there is an open question how to
assess whether a particular simulation has successfully recovered the binding pose seen in the
crystal structure. For example, in a recent review by Pagadala et al. [57] which evaluated several
different docking software programs, they used a cutoff of 2 Å to determine whether or not a
fully flexible docking program managed to find the ‘correct’ pose. This strategy makes sense
for cases where the protein’s unbiased fluctuations span a range less than 2 Å. The solid boxes
in the left hand panel of Fig 6 show the RMSD range (mean ±2σ) spanned by a non-interactive
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Narupa simulation run for 50 picoseconds initialized in the bound pose at 298 K. Fig 6 shows
that the ±2σ range is less than 2 Å for all but the trypsin + indole-aminidine testing system.
During user ‘training’ phases, the results from Fig 6 show that all of the user generated poses
are either within ±2σ of the mean RMSD, or else have an RMSD which is within 2 Å of the
crystal structure. During user ‘testing’ phases, where the binding guide was switched off and
the ligand identity was different for trypsin and neuraminidase, the results show more scatter,
exactly as we would expect. Nevertheless the results are encouraging. For trypsin, all of the
novice-generated testing poses lie within ±2σ of the mean RMSD. For neuraminidase and
HIV-1 protease, which are considerably more complicated tasks, the results are similarly
encouraging: 4/5 of the neuraminidase testing poses are within 2.08 Å RMSD of the crystal
structure; and 3/5 of the HIV-1 protease testing poses are within 2.15 Å RMSD of the crystal
structure. Below we discuss the results for each system in further detail.
3.2.1 Trypsin. Directly comparing the trypsin training and testing tasks for the same par-
ticipant shows that task accomplishment was better for all participants (ranging between 1.0Å
and 1.9Å lower) during the training task. Benzamidine, used during the training task, is a
small ligand and users had the benefit of trace atoms (Fig 6), explaining the good performance
on the task. During the testing task, Fig 6 shows that participants were all able to recreate the
amidine contact to Asp189, correctly aligning the indole-amidine benzamidine moiety. The
variation in RMSD can be attributed to the rest of the molecule, where users had no prior guid-
ance; variation in the extended scaffold between users can be seen in Fig 2A. Therefore, task
accomplishment for binding indole-amidine into trypsin could likely be improved by provid-
ing additional feedback to indicate poses that are energetically favourable.
3.2.2 Neuraminidase. Fig 6 shows the minimum achieved RMSD for the neuraminidase
training and testing tasks. All participants were able to recreate the original bound pose of osel-
tamivir in neuraminidase, getting within 1Å RMSD of the starting coordinates. The training
results gave better minimum ligand RMSDs compared to the testing task, where were between
0.3Å and 3.2Å higher when the results between the training and testing task are compared for
Fig 6. Minimum RMSD values for novice tasks. (Left) Showing the minimum achieved RMSD of each small ligand novices tried to dock, where each
participant is assigned a unique colour. Two ligands were docked for each system, in both ‘training’ and ‘testing’ phases; each ligand is denoted in Fig 2.
To determine the extent to which user-identified poses aligned with the native RMSD, a non-interactive Narupa simulation was run for 50 picoseconds
in the bound pose and the average RMSD (plus or minus two standard deviations) was calculated, shown as the purple box. The whiskers at the top of
each box span 1 Angstrom. (Right) The pose corresponding to the minimum RMSD value shown is on the left for each participant, overlaid on top of
one another. Testing tasks for the three are shown in the top row, training tasks are shown on the bottom.
https://doi.org/10.1371/journal.pone.0228461.g006
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the same participant (Fig 6). For the testing task, four out of five participants were able to place
zanamivir in the correct orientation, indicating that users recognized the shared scaffold
between oseltamivir and zanamavir (highlighted in green in Fig 2B). In particular, there was
very good alignment of polar moieties (e.g. the carboxylate group, the ring ether) between par-
ticipants (Fig 6). However, variation arose from the flexible nature of zanamivir (whereas osel-
tamivir was very consistently aligned throughout the molecule when participants completed
the task with the aid of trace atoms). This would suggest that an interface for completing drug
binding tasks using iMD-VR could benefit from being able to give ligand-centric feedback,
indicating whether functional groups are in an optimal geometry.
3.2.3 HIV-1 protease. Fig 6C shows the minimum achieved RMSD for the HIV-1 prote-
ase training and testing tasks. Likely owing to the increased size of amprenavir and the number
of rotatable bonds it has, both the training and test tasks for HIV-1 protease had a higher
degree of variation in minimum RMSD achieved when directly comparing results between the
two tasks for the same participant. Interestingly however, when rebinding amprenavir a sec-
ond time without trace atoms to guide them (testing task), three participants were able to get
an RMSD close to the training task, one of which was lower by 0.08Å. This may be a result of
users remembering the correct binding pose but it is nonetheless encouraging that iMD-VR
can be used to recreate poses of larger, torsionally complex molecules with limited iMD-VR
training. In particular, recreation of the contact between the amprenavir hydroxyl group and
Asp25B was generally good between both tasks (S4-C Fig in S1 File). For the training task,
Baker-Hubbard hydrogen bond analysis [58] on the minimum RMSD pose confirms this all
participants were able to establish this contact. In the testing task, 4/5 participants were able to
orientate the hydroxyl group and subsequently form a hydrogen bond to the catalytic Asp25A/
Asp25B catalytic residues. However, the HIV-1 protease ‘testing’ task still had the highest vari-
ation in minimum RMSD, as some participants had a poorer performance without having a
trace of the correct binding pose in the active site (the highest difference in RMSD between
training and testing tasks was 5.9Å). In the testing task, four participants were able to orientate
the hydroxyl group and subsequently form a hydrogen bond to the catalytic Asp25A/Asp25B
catalytic residues. However, when inspecting the two outliers, the overall scaffold of amprena-
vir is incorrectly orientated–regardless of whether the user had established the hydrogen bond-
ing contact to Asp25A and Asp25B.
4. Conclusions & future directions
In this paper, we have outlined an experimental protocol for setting up an iMD-VR simulation
for the purposes of interactively manipulating protein-ligand systems to recover experimen-
tally derived bound poses using iMD-VR. Utilizing this protocol, we have carried out studies
exploring iMD-VR as a strategy for interactively sampling the unbinding and rebinding of
ligands from proteins. The iMD-VR strategy enables this process to be accelerated compared
to the much larger timescales required in unbiased MD simulations. To the best of our knowl-
edge, this study represents the first time that iMD-VR has been extended to studies of complex
protein-ligand binding and unbinding dynamics.
Our results show that expert iMD-VR users are able to manipulate protein-ligand systems
to sample bound and unbound states. We also assessed the extent to which novice iMD-VR
uses were able to sample binding and unbinding pathways using a training phase followed by a
testing phase. Overall, the training phase showed slightly better task accomplishment; however,
binding was still generally successful for many of the users during the testing phase, with the
majority of users able to get within 2.15 Å RMSD of the experimental crystal structure, which
is a comparable level of accuracy to other fully flexible docking programs. [57] So as not to
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overwhelm participants with having to learn a new VR-rendering interface during training, we
took the decision to simplify the protein representations as shown in Supplementary videos
A–C in S1 File, showing a backbone representation along with a subset of those amino acids
which are known to have key interactions with the ligands, and which make a large contribu-
tion to the overall binding free energy. Encouragingly, even though only a limited set of bind-
ing interactions were shown, participants were still able to accurately rebind the ligands
studied herein, including amprenavir, whose size and flexibility makes the binding task partic-
ularly complicated. This raises an interesting question: Is it the quantity of rendered interac-
tions (i.e., showing all possible interactions) or the quality of rendered interactions (i.e.,
showing a few of the most important interactions) which enable better results to be obtained
during interactive docking tasks? At this stage, because we have not carried out the appropriate
control experiment, our results do not conclusively show that focusing on a few key interac-
tions enables better results, but this is an interesting avenue of future research which we intend
to explore in future work. Nonetheless, these results are especially encouraging given that our
cohort of novice users had a very limited time (less than 60 minutes) to be trained in both the
interface and each of the three protein-ligand systems. The results suggest that the iMD-VR
paradigm is sufficiently intuitive and affords adequate control to enable the sorts of detailed
manipulations required to carry out VR-enabled atomistic docking in a fully flexible MD envi-
ronment. Our ‘expert’ results show that iMD-VR users benefit from further training, given
their familiarity with the interface and the specific protein systems.
Beyond the quantitative analysis described herein, these studies also show that iMD-VR can
be used to reveal interesting qualitative features of protein-ligand unbinding, such as benzami-
dine not forming electrostatic contacts to Asp189 if it is incorrectly orientated and subsequently
being repelled out of the trypsin binding pocket (Supplementary video A.2 in S1 File), or
changes in the binding of amprenavir to tautomers of HIV-1 protease. In particular, the three-
dimensional interface aided in the identification of key interactions between the protein and
the ligand, as well as allowing the user to directly observe dynamical behaviours in real time.
Our iMD-VR framework enables users to quickly apply restraints to arbitrary subsets of
atoms, which can be turned on and off ‘on-the-fly’. The flexible application of restraints
enables the user to rapidly identify those regions where they would like to either explore or
dampen conformational flexibility–e.g., in loop domains. As a training strategy, we have found
that restraints enable less experienced iMD-VR users to familiarize themselves with a system
without the risk of inadvertently damaging the tertiary structure. For expert iMD-VR users,
restraints permit the sampling of sophisticated docking strategies that involve complex confor-
mational changes, like that in HIV-1 protease. In future work, we intend to carry out more
detailed studies on how to apply restraints so as to enable users to efficiently and accurately
carry out binding tasks.
We also intend to develop additional strategies to help iMD-VR users quickly formulate
and test binding hypotheses. For example, checkpoints will enable users to return the system
to previous states visited earlier in the simulation, along with additional audio and visual feed-
back to indicate to the user how structural manipulation influences the overall energy of the
system, and allowing the user to pause the simulation and carry out energy minimizations ‘on-
the-fly’. For the purposes of streamlining these particular studies and not overwhelming novice
users, we limited the studies described herein to a ‘backbone and key residue’ visualization
scheme for the proteins. While such a representation aims to facilitate locating the active site
and identifying key interactions, it makes it difficult to see unfavourable van der Waals interac-
tions between the ligand and protein. In future work, we will examine the extent to which dif-
ferent rendering strategies influence task accomplishment. Such methods will help inform
binding hypotheses in cases where the bound pose is unknown.
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Unbiased simulation of protein ligand-binding typically occur on timescales of milliseconds
or seconds [55, 56], and is therefore inaccessible to even the most sophisticated simulation
architectures without recourse to a biasing or acceleration method. There is evidence that find-
ing minimum energy pathways in hyperdimensional systems such as these is an “NP-hard”
problem (for which no optimal method exists). [59] Having established herein that iMD-VR
offers a reliable tool for experts and novices alike to generate accurate protein-ligand binding
poses, we intend to carry out studies aimed at analysing the user-generated iMD-VR pathways.
Specifically, we plan to analyse: (1) how closely user-generated iMD-VR pathways follow the
system’s minimum free energy path (MFEP); and (2) methods where iMD-VR pathways may
be used to recover free energies for association and dissociation. For example, the configura-
tions and pathways generated from iMD-VR (shown in Fig 3) could serve as initial guesses for
adaptive path-based free energy sampling algorithms like transition path sampling [60],
umbrella sampling [61], path-based metadynamics [62], forward flux sampling, [63] string
methods, [64] or boxed molecular dynamics (BXD). [65] In addition, the configurations gener-
ated during an iMD-VR run could be used to produce Markov state models for ligand binding
systems [8], by seeding the model with initial conditions which are not trapped within metasta-
ble energy minima [34, 66]. Whilst there are a number of details which require further investi-
gation in order to establish a reliable and integrated workflow for recovering free energies along
user-generated iMD-VR pathways, such a framework will enable us to explore the differences
in kinetics and thermodynamics between different ligands binding to the same protein target,
or the free energy landscape of the same drug binding to different protein mutants, with poten-
tial applications to areas like antimicrobial resistance. More broadly, the 3D iMD-VR interface
can be used to explore and sample cryptic binding configurations which may not be indicated
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